WO2020179781A1 - 五環式化合物の塩およびそれらの結晶 - Google Patents
五環式化合物の塩およびそれらの結晶 Download PDFInfo
- Publication number
- WO2020179781A1 WO2020179781A1 PCT/JP2020/008889 JP2020008889W WO2020179781A1 WO 2020179781 A1 WO2020179781 A1 WO 2020179781A1 JP 2020008889 W JP2020008889 W JP 2020008889W WO 2020179781 A1 WO2020179781 A1 WO 2020179781A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thieno
- compound
- diffraction
- crystals
- powder
- Prior art date
Links
- BLLSMPCWRPCBDL-UHFFFAOYSA-N CCOC(c1c(N)[s]c2c1CCN(C)C2)=O Chemical compound CCOC(c1c(N)[s]c2c1CCN(C)C2)=O BLLSMPCWRPCBDL-UHFFFAOYSA-N 0.000 description 2
- WXPVJHWBSNEEJS-UHFFFAOYSA-N CN(CC(Nc1c2cc[s]1)=O)C2=O Chemical compound CN(CC(Nc1c2cc[s]1)=O)C2=O WXPVJHWBSNEEJS-UHFFFAOYSA-N 0.000 description 2
- MBDLEUICTWNYLK-UHFFFAOYSA-N CN(CC1)Cc2c1c(C(N(c([s]cc1)c1C(N(C)C1)=O)C1=N1)=O)c1[s]2 Chemical compound CN(CC1)Cc2c1c(C(N(c([s]cc1)c1C(N(C)C1)=O)C1=N1)=O)c1[s]2 MBDLEUICTWNYLK-UHFFFAOYSA-N 0.000 description 2
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N CCOC(CC#N)=O Chemical compound CCOC(CC#N)=O ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- HUUPVABNAQUEJW-UHFFFAOYSA-N CN(CC1)CCC1=O Chemical compound CN(CC1)CCC1=O HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
- YPNJLKYQXUBRHJ-UHFFFAOYSA-N O=C(c1c(N2)[s]cc1)OC2=O Chemical compound O=C(c1c(N2)[s]cc1)OC2=O YPNJLKYQXUBRHJ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention presents pharmaceutically acceptable salts of pentacyclic compounds and crystals of pentacyclic compounds and pharmaceutically acceptable salts thereof, which have cholinergic neuronal activation and / or neuroprotective effects. Regarding.
- the present invention also relates to a pharmaceutical composition containing the above salt or crystal as an active ingredient.
- Non-Patent Document 1 cholinergic neurons that release acetylcholine as transmitters project widely from the Nucleus basalis and septal nucleus of the basal forebrain to the hippocampus, amygdala, and cerebral cortex, and memory, learning, and cognition. It is responsible for the regulation of attention.
- Non-Patent Document 2 cholinergic neurons in the pedunculopontine nucleus and dorsolateral tegmental nucleus of the brain stem project to the striatum, nucleus accumbens, substantia nigra and thalamus, and are thought to be involved in motivation and regulation of wakefulness.
- Non-Patent Documents 8-12 the role of cholinergic neurons in the basal portion of the forebrain has been clarified by analysis using many disorder model animals. Among them, it has been shown in a disorder model animal that the dysfunction of cholinergic neurons is correlated with the decrease in memory learning (Non-Patent Document 5-7), and the amount of acetylcholine is increased by a cholinesterase inhibitor to increase the amount of acetylcholine in cholinergic neurons. It has been shown that cognitive function is improved by increasing the function (Non-Patent Documents 8-12).
- NGF Nerve Growth Factor
- AD Alzheimer's dementia
- cholinergic neuron loss is seen from the early stage of onset, which is one of the pathological features of AD.
- senile plaque accumulation due to deposition of amyloid ⁇ and changes in neurofibrils due to aggregation of tau are also pathological features, and it is known that changes in neurofibrils increase with the progression of pathological conditions and cause nerve cell death.
- Changes in neurofibrils have been observed in the Nucleus basalis and the entorhinal infield cortex from the early stage of AD onset.
- Non-Patent Document 16-17 cholinergic neurons present in the Nucleus basalis are shed due to tau accumulation from an early stage, and their shedding and cognitive function It has been reported that the decrease in score correlates (Non-Patent Document 16-17).
- a genetically modified mouse Human tau P301S transgenic mouse
- a tau gene having a P301S mutation found in familial frontotemporal dementia hyperphosphorylation and abnormal accumulation of tau were observed as in AD. Get up.
- changes in neurofibrils which are pathological features of AD, occur (Non-Patent Document 18), causing cognitive dysfunction due to synaptic disorders, neurodegeneration, and neuronal loss.
- Human tau P301S transgenic mice are widely used as AD-like model animals (Non-patent documents 19-22), and by suppressing AD-like pathological changes in Human tau P301S transgenic mice. , It can be expected to improve the cognitive decline of Alzheimer's disease and suppress the progression of pathology.
- Non-Patent Document 23-25 analysis using a plurality of genetically modified mice and disorder model animals suggests axonal transport disorder as one of the causes of cholinergic nerve cell shedding.
- the hippocampal fornix amputation model impairs the axonal transport of cholinergic neurons that project from the septal field to the hippocampus, causing cell shedding by impairing the retrograde transport of molecules involved in survival and function ( Non-Patent Documents 26-28).
- This impaired retrograde transport is also seen in genetically modified mice (Non-Patent Documents 23 and 24), and the loss of cholinergic neurons due to hippocampal fornix amputation reflects one aspect of the pathology. Therefore, by suppressing / ameliorating the loss of cholinergic neurons in this disorder model, the effects of improving cognitive decline in Alzheimer's disease and suppressing the progression of pathological conditions can be expected.
- Lewy bodies In dementia with Lewy bodies (DLB; Dementia with Lewis bodies) and Parkinson's disease (PD; Parkinson disease), abnormal inclusion bodies (Lewy bodies) whose main component is ⁇ -synuclein appear in nerve cells, and nerve cells It is a progressive neurodegenerative disease that causes degeneration and shedding.
- a large distribution of Lewy bodies in the cerebral cortex causes cognitive dysfunction, and a large distribution in the brainstem causes Parkinsonism.
- psychiatric symptoms such as vision, hallucinations, delusions, and depressive symptoms, sleep disorders, and autonomic nervous symptoms are observed.
- Lewy body dementia is diagnosed if dementia occurs before or within 1 year of onset of Parkinsonism, but Parkinson's disease with dementia occurs if Parkinsonism has been present for more than 1 year before the onset of dementia. (PDD; Parkinson disease with with mentia) is diagnosed.
- PDD Parkinson disease with with mentia
- LBD Lewy body disease
- Non-Patent Documents 29-31 In dementia with Lewy bodies and Parkinson's disease with dementia, nerve cells of Meinert's basal ganglia, which is the origin of acetylcholinergic nerves, are degenerated and lost as in Alzheimer's disease. It has been reported that functional neuronal damage is observed (Non-Patent Documents 29-31). In addition, the progression of cholinergic nerve cell damage and cognitive decline are correlated (Non-Patent Document 29), and it has been shown that a cholinesterase inhibitor improves cognitive function. From these, it is shown that cognitive function is improved by improving the function of cholinergic neurons, and suppressing / improving the loss of cholinergic neurons in multiple disorder models is Alzheimer's dementia. Similarly, the effects of improving dementia of Lewy bodies and dementia of Parkinson's disease associated with dementia and suppressing the progression of disease state can be expected.
- the cognitive decline caused by the functional decline of cholinergic neurons can be improved by achieving the functional activation and / or neuroprotection of cholinergic neurons in clinical practice.
- Lapchak PA et al. “Effect of recombinant human nerve growth factor on presynaptic cholinergic function in rat hippocampal slices following partial septohippocampal lesions: measurements of [3H] acetylcholine -49.
- Gilmor ML et al. “Coordinate expression of the vesicular acetylcholine transporter and choline acetyltransferase following septohippocampal pathwaylesions” J.Neurochem. 71 (1998) 2411-20. Gu Het al.
- compound (I) The compound represented by the following formula (I) (5,10-dimethyl-5,6,9,10,11,12-hexahydropyrido [4'', 3'': 4', 5'] thieno [2] ',3':4,5]pyrimido[1,2-a]thieno[3,2-f][1,4]diazepine-4,13-dione, hereinafter also referred to as "compound (I)").
- the present inventors have found that they have a cholinergic nerve cell activating effect and / or a neuroprotective effect. Therefore, compound (I) has the potential as an ameliorating agent for cognitive decline caused by functional decline of cholinergic neurons.
- the present invention relates to the following ⁇ 1> to ⁇ 35>.
- ⁇ 1> 5,10-Dimethyl-5,6,9,10,11,12-hexahydropyrido[4′′,3′′:4′,5′]thieno[represented by the formula (I) 2',3':4,5]Pyrimido[1,2-a]thieno[3,2-f][1,4]diazepine-4,13-dione monohydrochloride or hydrobromide.
- E-type crystal of compound (I) monohydrochloride having the powder X-ray diffraction pattern of FIG. 6 in powder X-ray diffraction using CuK ⁇ as an X-ray source.
- the pharmaceutical composition according to ⁇ 16> which is a cholinergic neuron protective agent.
- a therapeutic agent for cognitive impairment which comprises the salt according to ⁇ 1> or the crystal according to any one of ⁇ 2> to ⁇ 15>.
- a method for treating cognitive dysfunction wherein the salt according to ⁇ 1> or the crystal according to any one of ⁇ 2> to ⁇ 15> is administered to a patient.
- ⁇ 23> Use of the salt according to ⁇ 1> or the crystal according to any one of ⁇ 2> to ⁇ 15> for producing a therapeutic agent for cognitive dysfunction.
- An Alzheimer's disease therapeutic agent comprising the salt according to ⁇ 1> or the crystal according to any one of ⁇ 2> to ⁇ 15>.
- ⁇ 25> A method for treating Alzheimer's disease, wherein the salt according to ⁇ 1> or the crystal according to any one of ⁇ 2> to ⁇ 15> is administered to a patient.
- ⁇ 26> The salt according to ⁇ 1> or the crystal according to any one of ⁇ 2> to ⁇ 15>, which is used for treating Alzheimer's disease.
- ⁇ 27> Use of the salt according to ⁇ 1> or the crystal according to any one of ⁇ 2> to ⁇ 15> for producing a therapeutic agent for Alzheimer's disease.
- a therapeutic agent for dementia with Lewy bodies which comprises the salt according to ⁇ 1> or the crystal according to any one of ⁇ 2> to ⁇ 15>.
- ⁇ 29> A method for treating dementia with Lewy bodies, wherein the salt according to ⁇ 1> or the crystal according to any one of ⁇ 2> to ⁇ 15> is administered to a patient.
- ⁇ 31> Use of the salt according to ⁇ 1> or the crystal according to any one of ⁇ 2> to ⁇ 15> for producing a therapeutic agent for dementia with Lewy bodies.
- a therapeutic agent for Parkinson's disease associated with dementia which comprises the salt according to ⁇ 1> or the crystal according to any one of ⁇ 2> to ⁇ 15>.
- ⁇ 33> A method for treating Parkinson's disease associated with dementia, wherein the salt according to ⁇ 1> or the crystal according to any one of ⁇ 2> to ⁇ 15> is administered to a patient.
- ⁇ 34> The salt according to ⁇ 1> or the crystal according to any one of ⁇ 2> to ⁇ 15>, which is used for treating Parkinson's disease associated with dementia.
- ⁇ 35> Use of the salt according to ⁇ 1> or the crystal according to any one of ⁇ 2> to ⁇ 15> for producing a therapeutic agent for Parkinson's disease associated with dementia.
- FIG. 1 is a powder X-ray diffraction pattern of the crystal of compound (I) obtained in Example 1.
- the horizontal axis represents the diffraction angle (2 ⁇ ), and the vertical axis represents the peak intensity.
- FIG. 2 is a powder X-ray diffraction pattern of the A-type crystal of compound (I) monohydrochloride obtained in Example 2.
- the horizontal axis represents the diffraction angle (2 ⁇ ), and the vertical axis represents the peak intensity.
- FIG. 3 is a powder X-ray diffraction pattern of the B-type crystal of compound (I) monohydrochloride obtained in Example 4.
- the horizontal axis represents the diffraction angle (2 ⁇ ), and the vertical axis represents the peak intensity.
- FIG. 1 is a powder X-ray diffraction pattern of the crystal of compound (I) obtained in Example 1.
- the horizontal axis represents the diffraction angle (2 ⁇ ), and the vertical axis represents the peak intensity.
- FIG. 4 is a powder X-ray diffraction pattern of the C-type crystal of compound (I) monohydrochloride obtained in Example 3.
- the horizontal axis represents the diffraction angle (2 ⁇ ), and the vertical axis represents the peak intensity.
- FIG. 5 is a powder X-ray diffraction pattern of the D-type crystal of compound (I) monohydrochloride obtained in Example 5.
- the horizontal axis represents the diffraction angle (2 ⁇ ), and the vertical axis represents the peak intensity.
- FIG. 6 is a powder X-ray diffraction pattern of the E-type crystal of compound (I) monohydrochloride obtained in Example 6.
- the horizontal axis represents the diffraction angle (2 ⁇ ), and the vertical axis represents the peak intensity.
- FIG. 5 is a powder X-ray diffraction pattern of the D-type crystal of compound (I) monohydrochloride obtained in Example 5.
- the horizontal axis represents the diffraction angle (2 ⁇ ), and the vertical
- FIG. 7 is a powder X-ray diffraction pattern of the F-type crystal of compound (I) monohydrochloride obtained in Example 7.
- the horizontal axis represents the diffraction angle (2 ⁇ ), and the vertical axis represents the peak intensity.
- FIG. 8 is a powder X-ray diffraction pattern of the crystals of compound (I) hydrobromide obtained in Example 8.
- the horizontal axis represents the diffraction angle (2 ⁇ ), and the vertical axis represents the peak intensity.
- FIG. 9 is a 13 C solid-state NMR spectrum of the A-type crystal of compound (I) monohydrochloride obtained in Example 2.
- the horizontal axis represents the chemical shift ( ⁇ ) and the vertical axis represents the peak intensity.
- FIG. 10 is a 13 C solid-state NMR spectrum of the B-type crystal of compound (I) monohydrochloride obtained in Example 4.
- the horizontal axis represents the chemical shift ( ⁇ ) and the vertical axis represents the peak intensity.
- FIG. 11 is a 13 C solid-state NMR spectrum of the C-type crystal of compound (I) monohydrochloride obtained in Example 3.
- the horizontal axis represents the chemical shift ( ⁇ ) and the vertical axis represents the peak intensity.
- FIG. 12 is a thermal analysis TG-DTA chart of the Form A crystal of compound (I) monohydrochloride obtained in Example 2.
- the horizontal axis shows the temperature
- the left vertical axis shows the weight change of TG
- the right vertical axis shows the heat flow rate of DTA.
- FIG. 13 is a thermal analysis TG-DTA chart of the B-type crystal of the compound (I) monohydrochloride obtained in Example 4.
- the horizontal axis shows the temperature, the left vertical axis shows the weight change of TG, and the right vertical axis shows the heat flow rate of DTA.
- FIG. 14 is a thermal analysis TG-DTA chart of the C-type crystal of the compound (I) monohydrochloride obtained in Example 3.
- the horizontal axis shows the temperature, the left vertical axis shows the weight change of TG, and the right vertical axis shows the heat flow rate of DTA.
- FIG. 15 is a thermal analysis TG-DTA chart of the D-type crystal of the compound (I) monohydrochloride obtained in Example 5.
- FIG. 16 is a thermal analysis TG-DTA chart of the E type crystal of the compound (I) monohydrochloride obtained in Example 6.
- the horizontal axis shows the temperature, the left vertical axis shows the weight change of TG, and the right vertical axis shows the heat flow rate of DTA.
- FIG. 17 is a thermal analysis TG-DTA chart of the F type crystal of the compound (I) monohydrochloride obtained in Example 7.
- the horizontal axis shows the temperature, the left vertical axis shows the weight change of TG, and the right vertical axis shows the heat flow rate of DTA.
- FIG. 16 is a thermal analysis TG-DTA chart of the E type crystal of the compound (I) monohydrochloride obtained in Example 6.
- the horizontal axis shows the temperature, the left vertical axis shows the weight change of TG, and the right vertical axis shows the heat flow rate of DTA.
- FIG. 17 is a thermal analysis TG-DTA chart of the F type crystal of the compound (
- FIG. 18 is a thermal analysis TG-DTA chart of the crystal of the compound (I) monohydrobromide obtained in Example 8.
- the horizontal axis shows the temperature
- the left vertical axis shows the weight change of TG
- the right vertical axis shows the heat flow rate of DTA.
- FIG. 19 shows a Raman spectrum of a type A crystal of compound (I) monohydrochloride obtained in Example 2.
- salt means a chemical substance consisting of compound (I), which is a basic component, and an acid having a specific equivalent number with respect to compound (I).
- salts used in the present specification include a salt with an inorganic acid, a salt with an organic acid, a salt with an acidic amino acid, and the like, and among them, a pharmaceutically acceptable salt is preferable.
- salts with inorganic acids include salts with hydrochloric acid, hydrobromic acid, sulfuric acid, nitrate, phosphoric acid and the like
- examples of salts with organic acids include acetic acid, succinic acid and fumal.
- Salts with organic carboxylic acids such as acids, maleic acid, tartaric acid, malic acid, citric acid, lactic acid, stearic acid, benzoic acid, methanesulfonic acid (mesylic acid), ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid
- Examples thereof include salts with organic sulfonic acids such as (tosyl acid), and among them, hydrochloric acid, hydrobromic acid and phosphoric acid are preferable.
- salts with acidic amino acids include salts with aspartic acid, glutamic acid and the like.
- the salt of the present invention may be anhydrous, hydrate or solvate.
- the hydrate or solvate refers to a solid formed by combining compound (I) or a salt thereof and a water molecule or a solvent molecule, respectively, even if the solid is a crystal.
- the solvent of the solvent mixture is, for example, a ketone solvent such as acetone, 2-butanone, cyclohexanone; an ester solvent such as methyl acetate or ethyl acetate; 1,2-dimethoxyethane, t-butyl methyl ether and the like.
- Ether-based solvents such as methanol, ethanol, 1-propanol and isopropanol
- polar solvents such as N-methyl-2-pyrrolidone, N, N-dimethylformamide and dimethylsulfoxide
- the number of water molecules or solvent molecules with respect to compound (I) or a salt thereof is not particularly limited, and may be, for example, one molecule or two molecules.
- crystal means an anhydride or hydrate crystal of compound (I) or a salt thereof.
- preferable compounds (I) and crystals of the hydrochloride and hydrobromide of compound (I) include: A crystal of compound (I) having diffraction peaks at diffraction angles (2 ⁇ 0.2°) of 9.0°, 11.1° and 23.6° in powder X-ray diffraction; In powder X-ray diffraction, the diffraction angle (2 ⁇ ⁇ 0.2 °) 9.0 °, 11.1 °, 14.5 °, 18.1 °, 20.0 °, 21.9 °, 23.6 ° , A crystal of compound (I) having diffraction peaks at 24.4°, 24.9° and 28.5°; A-type crystal of compound (I) monohydrochloride having diffraction peaks at diffraction angles (2 ⁇ ⁇ 0.2 °) of 11.6 °, 20.8 ° and 25.7 ° in powder X-ray diffraction; In powder X-ray diffraction, the diffraction angles (2 ⁇ ⁇ 0.2 °) of 9.
- the diffraction peaks in the powder X-ray diffraction described above, the chemical shifts in the 13C solid-state NMR spectrum, and the Raman shift peaks in Raman spectroscopy are the crystals of compound (I), the A to F type crystals of compound (I) monochloride, and It is peculiar to each crystal of compound (I) hydromonobromide, and is a peak characteristic of the crystal.
- the diffraction angle (2 ⁇ ) in powder X-ray diffraction may have an error within the range of ⁇ 0.2 °, so the above diffraction angle value is assumed to include a value within the range of about ⁇ 0.2 °. Need to be understood. Therefore, in a specific compound or a salt thereof, not only the crystals in which the peak diffraction angles in powder X-ray diffraction are completely the same, but also the crystals in which the peak diffraction angles are the same with an error of about ⁇ 0.2 ° are the same. , Included in the present invention.
- the peak intensity or full width at half maximum of the diffraction angle (2 ⁇ ) in powder X-ray diffraction has different measurement conditions and the size and shape of each particle of the powder crystal used as a measurement sample even if the crystal shape is the same. Due to variability, it varies from measurement to measurement and does not always show a constant peak intensity or full width at half maximum. Therefore, in the comparison of powder X-ray diffraction patterns, even if there is a difference in peak intensity or full width at half maximum at the same diffraction angle (2 ⁇ ), the difference does not mean that it is derived from a different crystal form.
- the crystal of the powder X-ray diffraction pattern having such a difference with respect to the diffraction peak characteristic of the specific crystal of the present invention has the same crystal form as the crystal of the present invention.
- "having the powder X-ray diffraction pattern of FIG. 1" means that the powder X-ray diffraction pattern having a characteristic diffraction peak is ⁇ 0.
- the powder X-ray diffraction pattern represented by FIG. not only in the case of matching within the error range of 2 °, but also in the case of powder X-ray diffraction patterns in which the characteristic diffraction angles match within the error range of ⁇ 0.2 ° but the peak intensity or half value width is different.
- all the crystals showing the powder X-ray diffraction pattern shown in FIG. 1 are the same crystals as the crystals of the present invention.
- chemical shift ( ⁇ 0.5 ppm) 164.0 ppm, 129.6 ppm and 36.5 ppm means “ 13 C under normal measurement conditions or substantially the same conditions as in the present specification”.
- a solid-state NMR spectrum measurement is performed, and each has a peak substantially equivalent to a chemical shift ( ⁇ 0.5 ppm) of 164.0 ppm, 129.6 ppm, and 36.5 ppm”.
- the chemical shift ⁇ in the 13 C solid state NMR spectrum may cause an error within a range of ⁇ 0.5 ppm, and thus the above-mentioned chemical shift value Needs to be understood as including numerical values in the range of about ⁇ 0.5 ppm. Therefore, the present invention includes not only a crystal whose chemical shifts in the 13 C solid state NMR spectrum completely match, but also a crystal whose chemical shifts match with an error of about ⁇ 0.5 ppm.
- “having a peak at a chemical shift ( ⁇ 0.5 ppm) of 164.0 ppm” means having a peak in the range of a chemical shift ( ⁇ ) of 163.5 ppm to 164.5 ppm. This means the same for other chemical shifts in the 13 C solid-state NMR spectrum.
- the Raman shift peak (cm -1 ) in Raman spectroscopy can have an error within the range of ⁇ 2 cm -1 , so the above peak value is understood to include the value within the range of ⁇ 2 cm -1. Needs to be done. Therefore, in a specific compound or a salt thereof, not only the crystals in which the Raman shift peaks in Raman spectroscopy are completely matched but also the crystals in which the Raman shift peaks are matched with an error of about ⁇ 2 cm -1 are the same. included.
- the peak intensity or full width at half maximum of Raman shift in Raman spectroscopy is measured due to differences in measurement conditions and variations in the size and shape of each particle of the powder crystal used as a measurement sample, even if the crystal shapes are the same. It varies from one to another and does not always show a constant peak intensity or full width at half maximum. Therefore, in comparison of Raman spectroscopic measurements, differences in peak intensity or full width at half maximum for the same Raman shift peak (cm -1 ) do not mean that the differences are derived from different crystal forms. .. Therefore, the Raman spectrum having such a difference with respect to the Raman shift peak characteristic of the particular crystal of the present invention means that the crystal has the same crystal form as the crystal of the present invention.
- “having the spectrum of FIG. 19 in Raman spectroscopy measurement” means that the Raman spectrum having a characteristic Raman shift peak (cm -1 ) is ⁇ 2 cm with respect to the Raman spectrum represented by FIG. not only if it matches within an error range of -1, even if the peak intensity or half width of those characteristic Raman shift peaks are matched within an error range of ⁇ 2 cm -1 different Raman spectrum, FIG. It means that all the crystals showing the Raman spectrum represented by 19 are the same crystals as the crystals of the present invention.
- Compound (I) may be produced by a method well known to those skilled in the art.
- compound (I) can be synthesized by the method described in Reference Examples described below.
- the salt of compound (I) according to the present invention can be obtained by a method for producing a normal salt. Specifically, for example, compound (I) is suspended or dissolved in a solvent by heating, if necessary, and then an acid is added to the resulting suspension or solution, followed by room temperature or cooling. However, it can be produced by stirring or leaving for several minutes to several days.
- the salt of compound (I) can be obtained as crystalline or amorphous. Further, the amorphous substance can be obtained by further performing an operation such as freeze-drying on these production methods, if necessary.
- solvents examples include alcohol solvents such as ethanol, 1-propanol and isopropanol; acetonitrile; ketone solvents such as acetone and 2-butanone; ester solvents such as ethyl acetate; saturated carbonization such as hexane and heptane. Hydrogen solvent; ether solvent such as t-butyl methyl ether or water can be mentioned. These solvents may be used alone or in combination of two or more.
- a crystal of compound (I) or a salt thereof can be produced by the above-mentioned method for producing compound (I) or a method for producing a salt thereof, or It can also be produced by heating and dissolving I) or a salt thereof in a solvent, cooling with stirring and crystallizing.
- the compound (I) or a salt thereof used for crystallization may be in any form, may be a solvate or a hydrate or an anhydrous, and may be amorphous or crystalline (from a plurality of polymorphs). It may be a mixture of these.
- Solvents used for crystallization include, for example, alcohol solvents such as methanol, ethanol, isopropanol, 1-propanol; acetonitrile; amide solvents such as N,N-dimethylformamide; ester solvents such as ethyl acetate; hexane and heptane. Examples thereof include saturated hydrocarbon solvents such as; ketone solvents such as acetone and 2-butanone; ether solvents such as t-butyl methyl ether; and water. Further, these solvents may be used alone or in combination of two or more.
- the amount of the solvent used can be appropriately selected with the lower limit being the amount at which the compound (I) or its salt is dissolved by heating or the amount at which the suspension can be agitated, and the upper limit being the amount at which the crystal yield does not significantly decrease. ..
- seed crystals may or may not be added.
- the temperature at which the seed crystal is added is not particularly limited, but is preferably 0 to 80 ° C.
- the temperature at which compound (I) or a salt thereof is dissolved by heating may be appropriately selected depending on the solvent, but the recrystallization solvent is preferably from 50 ° C. It is in the range of the temperature at which reflux is started, and more preferably 55 to 80 ° C.
- Cooling at the time of crystallization may include crystals (polymorphs) having different aspects when rapidly cooled, so it is desirable to appropriately adjust the cooling rate in consideration of the influence on the quality and particle size of the crystals. , Preferably, for example, cooling at a rate of 5-40 ° C./hour. More preferably, for example, cooling at a rate of 5 to 25 ° C./hour.
- the final crystallization temperature can be appropriately selected depending on the crystal yield and quality, but is preferably -25 to 30°C.
- the crystallized crystals can be separated by a normal filtration operation, the separated crystals can be washed with a solvent if necessary, and the crystals can be further dried to obtain the desired crystals.
- a solvent e.g., ethanol, acetone, 2-butanone, ethyl acetate, diethyl ether, t-butyl methyl ether, hexane and the like can be mentioned. Further, these solvents may be used alone or in combination of two or more.
- the crystals separated by the filtration operation can be appropriately dried by leaving them in the air or in a nitrogen stream, or by heating.
- the drying time the time until the residual solvent falls below a predetermined amount may be appropriately selected according to the production amount, the drying device, the drying temperature, etc.
- drying can be performed under ventilation or under reduced pressure.
- the degree of decompression may be appropriately selected according to the production amount, the drying apparatus, the drying temperature, and the like. After drying, the obtained crystals can be left in the air if necessary.
- the crystals of the compound (I) and the salt of the compound (I) obtained by the production method described above have a cholinergic neuron activating effect and / or as shown in the activity data in the pharmacological test examples described later. It has a neuroprotective effect and can be used as an ameliorating agent for cognitive decline caused by functional decline of cholinergic neurons.
- [Pharmaceutical composition] Another embodiment of the invention is a pharmaceutical composition containing crystals of compound (I) and pharmaceutically acceptable additives.
- the pharmaceutical composition can be prepared by mixing a pharmaceutically acceptable additive with the crystals of compound (I).
- the pharmaceutical composition according to the present invention can be produced according to a known method such as the method described in the 17th revised Japanese Pharmacopoeia General Formulation Regulations.
- the pharmaceutical composition according to this embodiment can be appropriately administered to a patient according to its dosage form.
- the dose of compound (I) according to the present invention varies depending on the degree of symptoms, age, sex, body weight, administration form / salt type, specific type of disease, etc., but is usually 1 for adults.
- the crystal of compound (I) of the present invention can be produced, for example, by the method described in the following Examples, and the effect of the compound can be confirmed by the method described in the following Test Examples. it can.
- the sample was precisely weighed in an aluminum sample pan and measured under the following conditions. (Measurement condition) Atmosphere: 100 mL / min Nitrogen gas Airflow Control: Empty aluminum sample pan Temperature rise rate: 10 ° C / min Sampling interval: 1 sec Measurement temperature range: room temperature to 320°C
- the 13 C solid-state NMR spectrum of the crystal was measured under the following conditions with a solid sample enclosed in a sample tube in an amount of about 300 mg.
- Equipment used Avance 400MHz (manufactured by Bruker) 7mm-CPMAS probe (manufactured by Bruker) Measurement nucleus: 13 C (resonance frequency 100.6248425 MHz) Measurement temperature: Room temperature Pulse mode: CPTOSS Measurement rotation speed: 5000 Hz Pulse repetition time: 3 sec Contact time: 1 msec Number of integrations: 5120 times Reference substance: Glycine (external standard: 176.03 ppm)
- the Raman spectrum of the crystal was measured under the following measurement conditions by placing the sample on the sample table of a microscopic Raman spectrometer.
- Diffraction grating 1200 lines/mm
- Objective lens 50x scanning style: Continuous exposure time: 5 seconds
- Total number of times 5 times Measurement range: 400 to 1800 cm -1 (Raman shift) Error: ⁇ 2cm -1
- Root temperature in the following examples and reference examples usually indicates about 10 ° C to about 35 ° C. % Indicates weight percent unless otherwise specified.
- Initiator TM or Initiator+ TM manufactured by Biotage was used.
- the silica gel used is Merck's Silica Gel60 (70-230 mesh ASTM) or Fuji Silysia Chemical's PSQ60B, or a prepack column ⁇ column: YAMAZEN's Hi-Flash TM Column (Silicagel), size: S ( 16 x 60 mm), M (20 x 75 mm), L (26 x 100 mm), 2 L (26 x 150 mm), 3 L (46 x 130 mm), or Biotage TM SNAP Ultra Silica Gel, size: 10 g , 25 g, or 50 g ⁇ was used.
- NH silica gel For NH silica gel, use CHROMATOREX NH-DM2035 manufactured by Fuji Silysia Chemical Ltd., or prepack column ⁇ column: Hi-Flash TM Column (Amino) manufactured by YAMAZEN, size: S (16 x 60 mm), M (20 x 75 mm). ), L (26 x 100 mm), 2 L (26 x 150 mm), 3 L (46 x 130 mm), or Wako Pure Chemical Industries, Ltd.
- Example 1 Preparation of crystals of compound (I) To 1.5 L of 0.3 M hydrochloric acid, 152.08 g of compound (I) was added, 450 ml of ethyl acetate was added to this solution, and the mixture was stirred for 5 minutes. The aqueous layer was separated, washed with 450 ml of ethyl acetate, and the insoluble material was filtered off. 100 ml of a 1N aqueous sodium hydroxide solution was added to the filtrate in a water bath at 20 ° C., and the mixture was stirred for 15 minutes.
- Example 2 Preparation of A-type Crystals of Compound (I) Monohydrochloride 101 mg of Compound (I) was added to a screw cap test tube. 0.2 mL of 1.5 M hydrochloric acid was added and dissolved. 1.8 mL of IPA was added, and after ultrasonic irradiation, the mixture was stirred at 40 ° C. for one day using a stirrer. After stirring at room temperature for an additional 1 hour, the sample was filtered using a filter (0.2 ⁇ m), rinsed with 0.5 mL of IPA/water (9/1, v/v), and ventilated under a nitrogen stream. Dried. The crystals were dried at 70 ° C. for about 1 hour to obtain the title crystals (103 mg).
- Powder X-ray diffraction peak (transmission method, 2 ⁇ 0.2°): 6.1°, 7.8°, 11.6°, 16.2°, 19.9°, 20.8°, 25.2 °, 25.7°, 26.9°, 29.9° 13 C-NMR (100MHz, solid state) ⁇ (ppm): 164.0, 162.5, 160.5, 153.9, 151.6, 150.7, 133.6, 131.1, 129.6 , 128.4, 126.9, 125.2, 123.7, 121.3, 120.3, 119.5, 53.7, 52.0, 50.9, 44.7, 36.5, 22 .6
- Raman shift peak (cm -1 ): 409,587,763,976,1428,1493,1688
- the powder X-ray diffraction pattern of the A-type crystal of compound (I) monohydrochloride obtained by the above method is shown in FIG. 2, the 13 C-solid-state NMR spectrum is shown in FIG. 9, and the thermogravimetric TG-DTA chart
- Example 3 Preparation of C-type Crystals of Compound (I) Monohydrochloride 1020 mg of Compound (I) was added to a screw cap test tube. 1.5 equivalents of hydrochloric acid (353 ⁇ L) was dissolved in 20 mL of methanol and added to the sample. The mixture was stirred at room temperature for 2 days using a stirrer. A sample was collected by filtration using a filter (0.2 ⁇ m). The obtained solid was dried under reduced pressure for about 2 hours and then dried at 70 ° C. for 1 hour to obtain the title crystals (1048 mg).
- Powder X-ray diffraction peak (transmission method, 2 ⁇ ⁇ 0.2 °): 6.0 °, 7.7 °, 9.7 °, 11.4 °, 15.8 °, 16.9 °, 18.1 °, 23.2°, 25.4°, 27.6° 13 C-NMR (100 MHz, solid state) ⁇ (ppm): 162.5, 160.5, 159.6, 153.8, 151.1, 134.1, 131.6, 128.4, 127.6. , 125.6, 120.0, 54.0, 52.6, 50.9, 44.3, 43.5, 38.9, 32.3, 22.4
- the powder X-ray diffraction pattern of the C-type crystal of compound (I) monohydrochloride obtained by the above method is shown in FIG. 4, the 13 C-solid-state NMR spectrum is shown in FIG. 11, and the thermogravimetric TG-DTA chart is shown in FIG. ..
- Example 4 Preparation of B-type Crystals of Compound (I) Monohydrochloride 303 mg of the hydrochloride crystals obtained in Example 3 was added to a platinum crucible and heated at 160 ° C. for 15 minutes to obtain the title crystals (293 mg). Powder X-ray diffraction peak (transmission method, 2 ⁇ ⁇ 0.2 °): 6.3 °, 9.7 °, 10.1 °, 17.9 °, 19.0 °, 19.4 °, 23.4 °, 26.3°, 27.3°, 32.0° 13 C-NMR (100 MHz, solid state) ⁇ (ppm): 162.0, 160.1, 153.8, 151.1, 133.4, 130.7, 128.3, 126.9, 125.6.
- Example 5 Preparation of Form D Crystals of Compound (I) Monohydrochloride 227 mg of the mixture of hydrochloride crystals obtained in each of Examples 2 and 3 and 8 mL of ethanol were added to a screw cap test tube. The mixture was stirred at 65 ° C. using a stirrer. After about 1 hour, ultrasonic waves were applied and the mixture was stirred at the same temperature for one day. The sample was collected by filtration using a filter (0.2 ⁇ m) to obtain the title crystal (203 mg).
- FIG. 5 shows a powder X-ray diffraction pattern of a D-type crystal of compound (I) monohydrochloride obtained by the above method
- FIG. 15 shows a thermal analysis TG-DTA chart.
- Example 6 Preparation of Form E Crystal of Compound (I) Monohydrochloride 108 mg of the hydrochloride crystal obtained in Example 2 and 5 mL of acetonitrile were added to a screw cap test tube. The mixture was stirred at 60 ° C. for one day using a stirrer, and the sample was collected by filtration using a filter (0.2 ⁇ m). The obtained solid and 5 mL of acetonitrile were added to the screw cap test tube again, and the mixture was stirred at 60 ° C. for one day using a stirrer. The crystals were collected by filtration under a nitrogen stream using a filter (0.2 ⁇ m) to obtain the title crystals (89.7 mg).
- FIG. 6 shows the powder X-ray diffraction pattern of the E type crystal of the compound (I) monohydrochloride obtained by the above method
- FIG. 16 shows the thermal analysis TG-DTA chart.
- Example 7 Preparation of Form F Crystals of Compound (I) Monohydrochloride Hydrochloride crystals 101 mg obtained in Example 2 and 5 mL of ethanol were added to a screw cap test tube. The mixture was stirred at 60 ° C. for one day using a stirrer. A sample was collected by filtration using a filter (0.2 ⁇ m). The obtained solid and 5 mL of ethanol were added to the screw cap test tube again, and the mixture was stirred at 60 ° C. for 4 hours using a stirrer. The crystals were collected by filtration using a filter (0.2 ⁇ m) to obtain the title crystals (75.0 mg).
- Powder X-ray diffraction peak (transmission method, 2 ⁇ 0.2°): 5.9°, 7.3°, 9.3°, 10.7°, 13.8°, 15.6°, 16.4 °, 18.7°, 25.1°, 26.8°
- the powder X-ray diffraction pattern of the F type crystal of the compound (I) monohydrochloride obtained by the above method is shown in FIG. 7, and the thermal analysis TG-DTA chart is shown in FIG.
- Example 8 Preparation of Crystals of Compound (I) Hydrohydrobromide
- Compound (I) 933 mg was added to a screw cap test tube.
- 1.5 equivalents (434 ⁇ L) of hydrobromic acid was dissolved in 20 mL of methanol and added to the sample. It stirred at room temperature for 3 days using the stirrer. The sample was collected by filtration using a filter (0.2 ⁇ m) and dried at 60 ° C. for 1 hour to obtain the title crystal (1111 mg).
- Powder X-ray diffraction peak (transmission method, 2 ⁇ 0.2°): 6.0°, 7.8°, 10.0°, 11.7°, 17.8°, 20.8°, 23.5 °, 24.5°, 25.2°, 27.3°
- a powder X-ray diffraction pattern of the compound (I) monohydrobromide obtained by the above method is shown in FIG. 8, and a thermal analysis TG-DTA chart is shown in FIG.
- the collected septal field is enzymatically treated with an enzyme solution containing 0.25% trypsin (15050-065, Thermo Fisher Scientific) and 0.01% DNase (D5025-150KU, Sigma) at 37 ° C. for 30 minutes. By doing so, the cells were dispersed. At this time, the enzymatic reaction was stopped by adding deactivated horse serum (26050-088, Thermo Fisher Scientific). The enzyme-treated solution was centrifuged at 1000 rpm for 3 minutes to remove the supernatant. 10 mL of medium was added to the obtained cell mass.
- Dulbecco's Modified Eagle's Medium (044-29765, WAKO) was supplemented with N2 supplements (17502-048, Thermo Fisher Scientific 122/140) and 1 mM Sodium pyruvic (S60) 10% (11360-070). , Thermo Fisher Scientific) was used.
- the cell mass to which the medium had been added was redispersed by gentle pipetting operation, and then centrifuged again at 1000 rpm for 3 minutes to remove the supernatant. 10 mL of medium was added to the obtained cell mass, and this cell dispersion was filtered through a 40 ⁇ m nylon mesh (Cell Strainer) to remove the cell mass to obtain a nerve cell suspension.
- the neuronal suspension was diluted with medium and 10% deactivated bovine serum (26140-079, Thermo Fisher Scientific) and 10% deactivated horse serum were added. Then, 100 ⁇ L/well was seeded in a 96-well incubator (354461, CORNING) previously coated with poly-D-lysine at an initial culture density of 1.4 ⁇ 10 5 cells/cm 2 . Seeded cells 5% CO 2 -95% air under were cultured two days at in 37 ° C. incubator, the medium was changed total volume of fresh medium 120 [mu] L, were incubated subsequently for 5 days. (2) Compound addition On the 7th day of the culture, drug addition was carried out as follows.
- the DMSO solution of the test compound was diluted in medium to 10 times the final concentration.
- NGF 450-01, PEPRO TECH, INC.
- the final DMSO concentration was 0.1% or less.
- only DMSO and NGF were added to the control group.
- a buffer containing 10 ⁇ M choline, 10 ⁇ M physostigmine and 6 mM KCl was added.
- the buffer was 125 mM NaCl, 25 mM 4-(2-hydroxyethyl)-1-piperazinecinethenesulfonic acid, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 2.2 mM CaCl 2 (2H 2 O), and 10 mM Glucose in sterile water.
- the final pH of the solution was adjusted to 7.4. After incubating the 96-well incubator with buffer under 5% CO 2 -95% air for 40 minutes in a 37° C. incubator, 80 ⁇ L was collected.
- ChAT choline acetyltransferase
- RNA purification was performed by the method described in the package insert of the kit. After RNA purification, total RNA concentration was measured by QIAexpert Instrument (QIAGEN). The cDNA was prepared using the SuperScript® VILO TM cDNA Synthesis Kit (# 11754: Thermo Fisher Scientific). The cDNA was prepared by the method described in the kit package insert. The prepared cDNA was diluted 4-fold with RNase free water, and the diluted cDNA solution was used as a sample.
- Taqman registered trademark
- Universal PCR Master Mix #43044437: Thermo Fisher Scientific
- Taqman registered trademark
- Gene Expression ResorpLass Rhs INVENTORIhsRhsRh
- Inventor RheaRs INVENTORIhEhRhsRs
- INVENTORIhedRs INVENTORIhedRs
- INVENTORIEDT #4331182
- 5 ⁇ l each were mixed to prepare a measurement sample solution.
- Quantitative prism chain reaction qPCR was performed by fluorescent probe method using ABI PRISM® 7900HT (Thermo Fisher Scientific). The analysis was performed by SDS2.4 (Thermo Fisher Scientific).
- the result was 56.4% at 10 mg / kg when the increase in the ChAT mRNA expression level of the compound-administered group of Reference Example 1 was calculated as a percentage with respect to the ChAT mRNA expression level of the vehicle-administered group.
- Acetylcholine (ACh) amount in rat Cerebrospinal fluid (CSF) (1) Background It has been clarified from rodent studies that the increase and decrease of neurotransmitters in the brain and in Cerebrospinal fluid (CSF) are correlated, and that the correlation is also understood in humans. (Lowe S et al. Psychopharmacology 219 (2012) 959-70.). Therefore, in order to detect the change in the amount of acetylcholine in the brain due to the test compound, the change in the amount of acetylcholine in CSF was evaluated. (2) Compound administration In this test, male Fischer 344 strain rats (Japan Charles River) having a body weight of about 150 to 250 g were used.
- the test compound was orally administered once a day for 3 days at 10 mg/kg.
- the medium used was 0.01N hydrochloric acid.
- CSF was collected from the cisterna in a tube containing an AChE inhibitor under pentobarbital anesthesia.
- the collected CSF was centrifuged at 3500 xg at 4 ° C. for 10 minutes, and the supernatant was collected.
- the recovered supernatant was frozen in liquid nitrogen and then stored at ⁇ 80 ° C.
- ChAT Choline acetyltransferase
- the number of ChAT-positive cells present along the main axis of the medial septum was measured by (Keyence). The results showed the number of ChAT-positive cells in the medium-administered group and the test compound-administered group as a percentage when the number of ChAT-positive cells in the administration start group (4 months old) was 100%. The results are expressed as the average value ⁇ standard error.
- the difference between the administration start group and the vehicle administration group (significant difference: *) and the difference between the vehicle administration group and the test compound group (significant difference: #) were analyzed by unpaired t-test. p ⁇ 0.05 was judged as a statistically significant difference. Statistical analysis was performed using GraphPad Prism version 7.02. The results are shown in Table 1.
- rat hippocampal fimbria fornix transection model a Sprague-Dawley male rat (Charles River Laboratories, Japan) weighing about 250-350 g was used. Rats were anesthetized by mixing three kinds of subcutaneous administration of midazolam (2 mg/kg), medetomidine hydrochloride (0.15 mg/kg) and butorphanol tartrate (2.5 mg/kg), and the rats were fixed on a stereotaxic apparatus (Narishige Co., Ltd.).
- the skull was exposed and the right skull was drilled to a width of 5 mm from the midline 2 mm posterior to Bregma.
- a razor with a width of 4 mm was inserted into the depth of 5.5 mm from Bregma to cut the hippocampal fimbria-fornix. After hemostasis, the scalp was sutured and the rat was returned to the cage after surgery to recover from anesthesia.
- the group in which the right skull was drilled to a width of 5 mm from the midline 2 mm behind Bregma and the razor was not inserted was defined as the sham surgery group.
- test compound was orally administered once a day for 5 to 9 days (Example 1: 10 mg / kg) or 7 days to 14 days (Example 3: 3 mg / kg).
- vehicle 0.01 N hydrochloric acid was used, and in the sham-operated group, the vehicle was orally administered once a day like the compound.
- a brain coronal frozen section with a thickness of 30 ⁇ m was obtained from a sample of the forebrain including the medial septal area using a sliding microtome (Leica, SM2000R). Made.
- ChAT Choline acetyltransferase positive cells
- VAChT vesicular acetylcholine transporter
- DAV staining DAB PERO XIDASE SUBSTRATE KIT (Vector, SK-4100) was performed using a VAChT antibody (Merck Millipore, ABN100).
- the number of ChAT-positive cells or OD of hippocampal VAChT in the vehicle-administered group and the test compound-administered group was shown as a percentage when the medial septal area ChAT-positive cells or hippocampal VAChT OD in the sham-operated group was defined as 100%. ..
- the results are expressed as mean ⁇ standard error.
- the difference between the vehicle administration group and the test compound group (significant difference: #) was analyzed by unpaired t-test. p ⁇ 0.05 was judged as a statistically significant difference.
- Statistical analysis was performed using GraphPad Prism version 7.02. The results are shown in Tables 2 and 3.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
<1>式(I)で表される5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオンの一塩酸塩または一臭化水素酸塩。
<3>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)9.0°、11.1°および23.6°に回折ピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオンの結晶。
<3.1>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)9.0°、11.1°、14.5°、18.1°、20.0°、21.9°、23.6°、24.4°、24.9°および28.5°に回折ピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオンの結晶。
<3.2>CuKαをX線源とする粉末X線回折において、図1の粉末X線回折パターンを有する5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオンの結晶。
<4>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)11.6°、20.8°および25.7°に回折ピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のA型結晶。
<4.1>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)6.1°、7.8°、11.6°、16.2°、19.9°、20.8°、25.2°、25.7°、26.9°および29.9°に回折ピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のA型結晶。
<4.2>CuKαをX線源とする粉末X線回折において、図2の粉末X線回折パターンを有する5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のA型結晶。
<4.3>グリシンを外部基準(176.03ppm)とする13C固体NMRスペクトルにおいて、ケミカルシフト(δ±0.5ppm)164.0ppm,129.6ppmおよび36.5ppmにピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のA型結晶。
<5>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)9.7°、10.1°および17.9°に回折ピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のB型結晶。
<5.1>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)6.3°、9.7°、10.1°、17.9°、19.0°、19.4°、23.4°、26.3°、27.3°および32.0°に回折ピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のB型結晶。
<5.2>CuKαをX線源とする粉末X線回折において、図3の粉末X線回折パターンを有する5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のB型結晶。
<5.3>グリシンを外部基準(176.03ppm)とする13C固体NMRスペクトルにおいて、ケミカルシフト(δ±0.5ppm)160.1ppm,133.4ppmおよび130.7ppmにピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のB型結晶。
<6>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)6.0°、7.7°および16.9°に回折ピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のC型結晶。
<6.1>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)6.0°、7.7°、9.7°、11.4°、15.8°、16.9°、18.1°、23.2°、25.4°および27.6°に回折ピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のC型結晶。
<6.2>CuKαをX線源とする粉末X線回折において、図4の粉末X線回折パターンを有する5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のC型結晶。
<6.3>グリシンを外部基準(176.03ppm)とする13C固体NMRスペクトルにおいて、ケミカルシフト(δ±0.5ppm)159.6ppm,127.6ppmおよび38.9ppmにピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のC型結晶。
<7>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)6.6°、14.6°および26.4°に回折ピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のD型結晶。
<7.1>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)6.6°、14.6°、16.1°、20.5°、21.0°、23.0°、24.5°、26.4°、28.0°および32.5°に回折ピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のD型結晶。
<7.2>CuKαをX線源とする粉末X線回折において、図5の粉末X線回折パターンを有する5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のD型結晶。
<8>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)6.4°、11.3°および27.3°に回折ピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のE型結晶。
<8.1>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)6.4°、11.3°、15.7°、18.0°、19.2°、22.8°、24.6°、25.4°、26.0°および27.3°に回折ピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のE型結晶。
<8.2>CuKαをX線源とする粉末X線回折において、図6の粉末X線回折パターンを有する化合物(I)一塩酸塩のE型結晶。
<9>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)7.3°、9.3°および10.7°に回折ピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のF型結晶。
<9.1>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)5.9°、7.3°、9.3°、10.7°、13.8°、15.6°、16.4°、18.7°、25.1°および26.8°に回折ピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のF型結晶。
<9.2>CuKαをX線源とする粉末X線回折において、図7の粉末X線回折パターンを有する5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一塩酸塩のF型結晶。
<10>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)7.8°、24.5°および25.2°に回折ピークを有する5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一臭化水素酸塩の結晶。
<10.1>CuKαをX線源とする粉末X線回折において、回折角度(2θ±0.2°)6.0°、7.8°、10.0°、11.7°、17.8°、20.8°、23.5°、24.5°、25.2°および27.3°に回折ピークを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一臭化水素酸塩の結晶。
<10.2>CuKαをX線源とする粉末X線回折において、図8の粉末X線回折パターンを有する5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン一臭化水素酸塩の結晶。
<11>ラマン分光測定において、587cm-1にラマンシフトピーク(±2cm-1)を有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオンの一塩酸塩のA型結晶。
<12>ラマン分光測定において、587cm-1、1428cm-1および1493cm-1にラマンシフトピーク(±2cm-1)を有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオンの一塩酸塩のA型結晶。
<13>ラマン分光測定において、587cm-1、763cm-1、1428cm-1、1493cm-1および1688cm-1にラマンシフトピーク(±2cm-1)を有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオンの一塩酸塩のA型結晶。
<14>ラマン分光測定において、409cm-1、587cm-1、763cm-1、976cm-1、1428cm-1、1493cm-1および1688cm-1にラマンシフトピーク(±2cm-1)を有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオンの一塩酸塩のA型結晶。
<15>ラマン分光測定において、図19のスペクトルを有する、5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオンの一塩酸塩のA型結晶。
<16><1>記載の塩または<2>~<15>のいずれか一項に記載の結晶を含有する医薬組成物。
<17>コリン作動性神経細胞賦活剤である<16>記載の医薬組成物。
<18>コリン作動性神経細胞保護剤である<16>記載の医薬組成物。
<19>認知機能障害の治療のための<16>記載の医薬組成物。
<20><1>記載の塩または<2>~<15>のいずれか一項に記載の結晶を含有する、認知機能障害の治療剤。
<21><1>記載の塩または<2>~<15>のいずれか一項に記載の結晶を患者に投与する、認知機能障害の治療方法。
<22>認知機能障害の治療に使用される、<1>記載の塩または<2>~<15>のいずれか一項に記載の結晶。
<23>認知機能障害の治療剤を製造するための、<1>記載の塩または<2>~<15>のいずれか一項に記載の結晶の使用。
<24><1>記載の塩または<2>~<15>のいずれか一項に記載の結晶を含有する、アルツハイマー病治療剤。
<25><1>記載の塩または<2>~<15>のいずれか一項に記載の結晶を患者に投与する、アルツハイマー病の治療方法。
<26>アルツハイマー病の治療に使用される、<1>記載の塩または<2>~<15>のいずれか一項に記載の結晶。
<27>アルツハイマー病の治療剤を製造するための、<1>記載の塩または<2>~<15>のいずれか一項に記載の結晶の使用。
<28><1>記載の塩または<2>~<15>のいずれか一項に記載の結晶を含有する、レビー小体型認知症治療剤。
<29><1>記載の塩または<2>~<15>のいずれか一項に記載の結晶を患者に投与する、レビー小体型認知症の治療方法。
<30>レビー小体型認知症の治療に使用される、<1>記載の塩または<2>~<15>のいずれか一項に記載の結晶。
<31>レビー小体型認知症の治療剤を製造するための、<1>記載の塩または<2>~<15>のいずれか一項に記載の結晶の使用。
<32><1>記載の塩または<2>~<15>のいずれか一項に記載の結晶を含有する、認知症を伴うパーキンソン病治療剤。
<33><1>記載の塩または<2>~<15>のいずれか一項に記載の結晶を患者に投与する、認知症を伴うパーキンソン病の治療方法。
<34>認知症を伴うパーキンソン病の治療に使用される、<1>記載の塩または<2>~<15>のいずれか一項に記載の結晶。
<35>認知症を伴うパーキンソン病の治療剤を製造するための、<1>記載の塩または<2>~<15>のいずれか一項に記載の結晶の使用。
粉末X線回折において、回折角度(2θ±0.2°)9.0°、11.1°および23.6°に回折ピークを有する、化合物(I)の結晶;
粉末X線回折において、回折角度(2θ±0.2°)9.0°、11.1°、14.5°、18.1°、20.0°、21.9°、23.6°、24.4°、24.9°および28.5°に回折ピークを有する、化合物(I)の結晶;
粉末X線回折において、回折角度(2θ±0.2°)11.6°、20.8°および25.7°に回折ピークを有する、化合物(I)一塩酸塩のA型結晶;
粉末X線回折において、回折角度(2θ±0.2°)6.1°、7.8°、11.6°、16.2°、19.9°、20.8°、25.2°、25.7°、26.9°および29.9°に回折ピークを有する、化合物(I)一塩酸塩のA型結晶;
13C固体NMRスペクトルにおいて、化学シフト(δ±0.5ppm)164.0ppm、129.6ppmおよび36.5ppmにピークを有する、化合物(I)一塩酸塩のA型結晶;
ラマン分光測定において、587cm-1にラマンシフトピーク(±2cm-1)を有する、化合物(I)一塩酸塩のA型結晶;
ラマン分光測定において、587cm-1、1428cm-1および1493cm-1にラマンシフトピーク(±2cm-1)を有する、化合物(I)一塩酸塩のA型結晶;
ラマン分光測定において、587cm-1、763cm-1、1428cm-1、1493cm-1および1688cm-1にラマンシフトピーク(±2cm-1)を有する、化合物(I)一塩酸塩のA型結晶;
ラマン分光測定において、409cm-1、587cm-1、763cm-1、976cm-1、1428cm-1、1493cm-1および1688cm-1にラマンシフトピーク(±2cm-1)を有する、化合物(I)一塩酸塩のA型結晶;
ラマン分光測定において、実質的に図19に示すスペクトルを有する、化合物(I)一塩酸塩のA型結晶;
粉末X線回折において、回折角度(2θ±0.2°)9.7°、10.1°および17.9°に回折ピークを有する、化合物(I)一塩酸塩のB型結晶;
粉末X線回折において、回折角度(2θ±0.2°)6.3°、9.7°、10.1°、17.9°、19.0°、19.4°、23.4°、26.3°、27.3°および32.0°に回折ピークを有する、化合物(I)一塩酸塩のB型結晶;
13C固体NMRスペクトルにおいて、化学シフト(δ±0.5ppm)160.1ppm、133.4ppmおよび130.7ppmにピークを有する、化合物(I)一塩酸塩のB型結晶;
粉末X線回折において、回折角度(2θ±0.2°)6.0°、7.7°および16.9°に回折ピークを有する、化合物(I)一塩酸塩のC型結晶;
粉末X線回折において、回折角度(2θ±0.2°)6.0°、7.7°、9.7°、11.4°、15.8°、16.9°、18.1°、23.2°、25.4°および27.6°に回折ピークを有する、化合物(I)一塩酸塩のC型結晶;
13C固体NMRスペクトルにおいて、化学シフト(δ±0.5ppm)159.6ppm、127.6ppmおよび38.9ppmにピークを有する、化合物(I)一塩酸塩のC型結晶;
粉末X線回折において、回折角度(2θ±0.2°)6.6°、14.6°および26.4°に回折ピークを有する、化合物(I)一塩酸塩のD型結晶;
粉末X線回折において、回折角度(2θ±0.2°)6.6°、14.6°、16.1°、20.5°、21.0°、23.0°、24.5°、26.4°、28.0°および32.5°に回折ピークを有する、化合物(I)一塩酸塩のD型結晶;
粉末X線回折において、回折角度(2θ±0.2°)6.4°、11.3°および27.3°に回折ピークを有する、化合物(I)一塩酸塩のE型結晶;
粉末X線回折において、回折角度(2θ±0.2°)6.4°、11.3°、15.7°、18.0°、19.2°、22,8°、24.6°、25.4°、26.0°および27.3°に回折ピークを有する、化合物(I)一塩酸塩のE型結晶;
粉末X線回折において、回折角度(2θ±0.2°)7.3°、9.3°および10.7°に回折ピークを有する、化合物(I)一塩酸塩のF型結晶;
粉末X線回折において、回折角度(2θ±0.2°)5.9°、7.3°、9.3°、10.7°、13.8°、15.6°、16.4°、18.7°、25.1°および26.8°に回折ピークを有する、化合物(I)一塩酸塩のF型結晶;
粉末X線回折において、回折角度(2θ±0.2°)7.8°、24.5°および25.2°に回折ピークを有する、化合物(I)一臭化水素酸塩の結晶;
粉末X線回折において、回折角度(2θ±0.2°)6.0°、7.8°、10.0°、11.7°、17.8°、20.8°、23.5°、24.5°、25.2°および27.3°に回折ピークを有する、化合物(I)一臭化水素酸塩の結晶などを挙げることができる。
化合物(I)は、当業者に周知な方法により製造されたものであってもよい。例えば、化合物(I)は、後述する参考例に記載の方法で合成することができる。
本発明に係る化合物(I)の塩は、通常の塩を製造する方法により得ることができる。具体的には、例えば、化合物(I)を溶媒に、必要に応じて加温して、懸濁または溶解させ、次いで、得られる懸濁液または溶液に、酸を加え、室温下あるいは冷却しながら数分から数日間、撹拌または放置することにより、製造することができる。これらの製造方法により、化合物(I)の塩を、結晶または非晶質として得ることができる。また、非晶質は、これらの製造方法に、必要に応じて、さらに凍結乾燥等の操作を行うことにより得ることもできる。ここで使用する溶媒としては、例えばエタノール、1-プロパノール、イソプロパノール等のアルコール系溶媒;アセトニトリル;アセトン、2-ブタノン等のケトン系溶媒;酢酸エチル等のエステル系溶媒;ヘキサン、ヘプタン等の飽和炭化水素系溶媒;t-ブチルメチルエーテル等のエーテル系溶媒または水を挙げることができる。これらの溶媒は単独で使用してもよく、2種以上を混合して使用してもよい。
化合物(I)またはその塩の結晶は、上述の化合物(I)の製造方法、またはその塩の製造方法により製造することができ、または、化合物(I)またはその塩を、溶媒中で加熱溶解し、攪拌下冷却して晶析することにより、製造することもできる。
本発明の他の実施形態は、化合物(I)の結晶および薬剤学的に許容される添加物を含有する医薬組成物である。医薬組成物は、薬剤学的に許容される添加物を化合物(I)の結晶と混和することにより製造することができる。本発明に係る医薬組成物は例えば第十七改正日本薬局方の製剤総則に記載の方法など既知の方法に従って製造することができる。
本実施形態に係る医薬組成物は、その剤形に応じて適切に患者に投与することができる。
(透過法条件)
X線源:CuKα
電圧:45kV
電流:40mA
光学系:集束ミラー
ソーラースリット:0.02°
検出器:X’Celerator(半導体検出器)
スキャン範囲:5°~35°
ステップサイズ:0.017°
スキャンステップ時間:600sec
サンプルホルダー:カプトン膜
(反射法条件)
X線源:CuKα
電圧:50kV
電流:300mA
スリット:発散スリット0.5mm、散乱スリット開放、受光スリット開放
検出器:シンチレーションカウンター
スキャン速度:5°/min
サンプリング間隔:0.02°
スキャン範囲:5°~35°
サンプルホルダー:アルミニウム製ホルダー
(測定条件)
雰囲気:100mL/min窒素ガス気流下
対照:空のアルミニウム製試料パン
昇温速度:10℃/min
サンプリング間隔:1sec
測定温度範囲:室温~320℃
(測定条件)
使用装置:Avance400MHz(BRUKER社製)7mm-CPMASプローブ(BRUKER社製)
測定核:13C(共鳴周波数 100.6248425MHz)
測定温度:室温
パルスモード:CPTOSS測定
回転数:5000Hz
パルス繰り返し時間:3sec
コンタクトタイム:1msec
積算回数:5120回
基準物質:グリシン(外部基準:176.03ppm)
(測定条件)
使用装置:RENISHAWラマンマイクロスコープinVia Reflex
レーザー波長:785nm
回折格子:1200lines/mm
対物レンズ:50倍
走査様式:連続
露光時間:5秒
積算回数:5回
測定範囲:400~1800cm-1(ラマンシフト)
誤差:±2cm-1
DMSO:ジメチルスルホキシド
IPA:イソプロパノール
n-:ノルマル
TEA:トリエチルアミン
THF:テトラヒドロフラン
1H-NMR:プロトン核磁気共鳴スペクトルメトリー
MS:マススペクトルメトリー
s:シングレット、d:ダブレット、t:トリプレット、q:カルテット、m:マルチプレット、br.s:ブロードシングレット。
NHシリカゲルは、富士シリシア化学(株)製CHROMATOREX NH-DM2035を用いるか、プレパックカラム{カラム:YAMAZEN社製 Hi-FlashTM Column(Amino)、サイズ:S(16×60mm)、M(20×75mm)、L(26×100mm)、2L(26×150mm)、3L(46×130mm)のいずれか、もしくは和光純薬工業社製 プレセップTM(ルアーロック)NH2(HC)、サイズ:タイプM(14g/25mL)、タイプL(34g/70mL)、タイプ2L(50g/100mL)、タイプ3L(110g/200mL)のいずれか}を用いた。
中性アルミナはAluminium oxide 90 active neutral,70-230mesh,Merck,E6NXXを用いた。
5,10-ジメチル-5,6,9,10,11,12-ヘキサヒドロピリド[4’’,3’’:4’,5’]チエノ[2’,3’:4,5]ピリミド[1,2-a]チエノ[3,2-f][1,4]ジアゼピン-4,13-ジオン(以下化合物(I)という。)の合成
1-メチル-4-ピペリドン(CAS No.1445-73-4)(51.5mL,442mmol)、エチルシアノアセテート(CAS No.105-56-6)(47.2mL,442mmol)、硫黄(CAS No.7704-34-9)(14.2g,442mmol)およびエタノール(800mL)の混合物に室温でTEA(61.6mL,442mmol)を加えた。反応混合物を40℃で15時間撹拌した後、減圧下濃縮した。残渣をカラムクロマトグラフィー(NHシリカゲル、酢酸エチル)で精製した。得られた濃縮残渣を酢酸エチルでトリチュレーションした。沈殿物をろ取し、酢酸エチルで洗浄し、そして減圧下に乾燥して、標記化合物(58.4g)を得た。
1H-NMR(400MHz,CDCl3)δ(ppm):1.33(t,J=7.0Hz,3H),2.44(s,3H),2.62-2.70(m,2H),2.79-2.88(m,2H),3.37(t,J=2.0Hz,2H),4.26(q,J=7.3Hz,2H),5.97(br.s,2H).
MS(ESI)m/z:241[M+H]+
サルコシン(790mg,8.87mmol)の水(12mL)溶液へ、1H,2H,4H-チエノ[2,3-d][1,3]オキサジン-2,4-ジオン(CAS No.103979-54-0)(600mg,3.55mmol)を加えた。反応混合物を1.5時間加熱還流した。反応混合物を室温まで冷却した。反応混合物へクロロホルムを加え、有機層を分離した。水層をクロロホルム(2回)、酢酸エチル(3回)で抽出した。合わせた有機層を無水硫酸ナトリウム上で乾燥し、ろ過し、ろ液を減圧下に濃縮した。得られた固体を乾燥し、標記化合物(430mg)を得た。
1H-NMR(400MHz,CDCl3)δ(ppm):3.23(s,3H),3.99(s,2H),6.90(d,J=5.9Hz,1H),7.29(d,J=5.7Hz,1H),8.39(br.s,1H).
MS(ESI)m/z:197[M+H]+
工程(2)で得た4-メチル-3,4-ジヒドロ-1H-チエノ[2,3-e][1,4]ジアゼピン-2,5-ジオン(1.00g,5.10mmol)、工程(1)で得たエチル 2-アミノ-6-メチル-4,5,6,7-テトラヒドロチエノ[2,3-c]ピリジン-3-カルボキシレート(1.84g,7.64mmol),および1,4-ジオキサン(30mL)の混合物へ、オキシ塩化リン(1.43mL,15.3mmol)を室温で加えた。反応混合物を室温で5分攪拌し、90℃で2時間撹拌した。室温まで冷却した反応混合物に、ナトリウム エトキシド(20%エタノール溶液、21.7mL,56.1mmol)を5分かけて加えた。反応混合物を室温で1.5時間攪拌した。反応混合物に酢酸エチル、飽和炭酸水素ナトリウム水溶液、そして水を順次加え、有機層を分離した。水層を酢酸エチルで抽出した。合せた有機層を無水硫酸マグネシウム上で乾燥し、ろ過し、ろ液を減圧下に濃縮した。残渣をカラムクロマトグラフィー(シリカゲル、20%-50%メタノール/酢酸エチル)で精製した。得られた固体をエタノールでトリチュレーションし、沈殿物をろ取した。得られた固体をエタノールで洗浄し、減圧下に乾燥して標記化合物(712mg)を得た。
1H-NMR(400MHz,CDCl3)δ(ppm):2.52(s,3H),2.71-2.87(m,2H),3.05-3.30(m,5H),3.59-3.75(m,2H),4.23(d,J=14.8Hz,1H),4.57(d,J=14.8Hz,1H),7.35(d,J=6.2Hz,1H),7.39(d,J=5.9Hz,1H).
MS(ESI)m/z:373[M+H]+
化合物(I)の結晶の調製
0.3M塩酸1.5Lに化合物(I)152.08gを加え、この溶液に酢酸エチル450mlを加えて5分間攪拌した。水層を分離し、酢酸エチル450mlで洗い、不溶物をろ去した。ろ液に20℃水浴中1N水酸化ナトリウム水溶液100mlを加え15分攪拌した。この混合物中に1N水酸化ナトリウム水溶液350mlを加え、生じた懸濁液を2時間30分攪拌した。生じた結晶をろ取し、水300ml、450ml、300ml、エタノール300ml、350mlおよび300mlで順次洗浄し、減圧下乾燥して標記結晶141.7gを得た。
粉末X線回折ピーク(反射法、2θ±0.2°):9.0°、11.1°、14.5°、18.1°、20.0°、21.9°、23.6°、24.4°、24.9°、28.5°
上記方法により得られた化合物(I)結晶の粉末X線回折パターンを図1に示す。
化合物(I)一塩酸塩のA型結晶の調製
化合物(I) 101mgをねじ口試験管に添加した。1.5M 塩酸0.2mLを加え溶解した。IPA 1.8mLを添加し、超音波照射後、スターラーを用いて40℃で一日攪拌した。室温にてさらに1時間攪拌後、フィルター(0.2μm)を用いて試料をろ取し、0.5 mLのIPA/水(9/1,v/v)でリンスし、窒素気流下で通風乾燥した。70℃で約1時間乾燥させ、標記結晶を得た(103mg)。
粉末X線回折ピーク(透過法、2θ±0.2°):6.1°、7.8°、11.6°、16.2°、19.9°、20.8°、25.2°、25.7°、26.9°、29.9°
13C-NMR(100MHz、solid state)δ(ppm):164.0,162.5,160.5,153.9,151.6,150.7,133.6,131.1,129.6,128.4、126.9,125.2,123.7,121.3,120.3、119.5,53.7,52.0,50.9,44.7,36.5,22.6
ラマンシフトピーク(cm-1):409、587、763、976、1428、1493、1688
上記方法により得られた化合物(I)一塩酸塩のA型結晶の粉末X線回折パターンを図2に、13C-固体NMRスペクトルを図9に、熱分析TG-DTAチャートを図12に、ラマンスペクトルを図19に、それぞれ示す。
化合物(I)一塩酸塩のC型結晶の調製
化合物(I) 1020mgをねじ口試験管に添加した。1.5当量の塩酸(353μL)を20mLのメタノールに溶解し、これを試料に加えた。スターラーを用いて室温にて2日間攪拌した。フィルター(0.2μm)を用いて試料をろ取した。得られた固体を約2時間減圧乾燥後、70℃で1時間乾燥させ、標記結晶を得た(1048mg)。
粉末X線回折ピーク(透過法、2θ±0.2°):6.0°、7.7°、9.7°、11.4°、15.8°、16.9°、18.1°、23.2°、25.4°、27.6°
13C-NMR(100MHz、solid state)δ(ppm):162.5,160.5,159.6,153.8,151.1,134.1,131.6,128.4,127.6,125.6,120.0,54.0,52.6,50.9,44.3,43.5,38.9,32.3,22.4
上記方法により得られた化合物(I)一塩酸塩のC型結晶の粉末X線回折パターンを図4に、13C-固体NMRスペクトルを図11に、熱分析TG-DTAチャートを図14に示す。
化合物(I)一塩酸塩のB型結晶の調製
実施例3で得られる塩酸塩結晶 303mgを白金製るつぼに加え、160℃で15分加熱し、標記結晶を得た(293mg)。
粉末X線回折ピーク(透過法、2θ±0.2°):6.3°、9.7°、10.1°、17.9°、19.0°、19.4°、23.4°、26.3°、27.3°、32.0°
13C-NMR(100MHz、solid state)δ(ppm):162.0,160.1,153.8,151.1,133.4,130.7,128.3,126.9,125.6,120.3,51.2,43.6,32.3,22.3
上記方法により得られた化合物(I)一塩酸塩のB型結晶の粉末X線回折パターンを図3に、13C-固体NMRスペクトルを図10に、熱分析TG-DTAチャートを図13に示す。
化合物(I)一塩酸塩のD型結晶の調製
実施例2,3でそれぞれ得られる塩酸塩結晶の混合物 227mgおよびエタノール8mLをねじ口試験管に添加した。スターラーを用いて65℃にて攪拌した。約1時間後、超音波照射し、同温度で一日攪拌した。フィルター(0.2μm)を用いて試料をろ取し、標記結晶を得た(203mg)。
粉末X線回折ピーク(透過法、2θ±0.2°):6.6°、14.6°、16.1°、20.5°、21.0°、23.0°、24.5°、26.4°、28.0°、32.5°
上記方法により得られた化合物(I)一塩酸塩のD型結晶の粉末X線回折パターンを図5に、熱分析TG-DTAチャートを図15に示す。
化合物(I)一塩酸塩のE型結晶の調製
実施例2で得られる塩酸塩結晶108mgおよびアセトニトリル5mLをねじ口試験管に添加した。スターラーを用いて60℃にて一日攪拌し、フィルター(0.2μm)を用いて試料をろ取した。得られた固体およびアセトニトリル5mLを再度ねじ口試験管に添加し、スターラーを用いて60℃にて一日攪拌した。フィルター(0.2μm)を用いて窒素気流下にてろ取し、標記結晶を得た(89.7mg)。
粉末X線回折ピーク(透過法、2θ±0.2°):6.4°、11.3°、15.7°、18.0°、19.2°、22.8°、24.6°、25.4°、26.0°、27.3°
上記方法により得られた化合物(I)一塩酸塩のE型結晶の粉末X線回折パターンを図6に、熱分析TG-DTAチャートを図16に示す。
化合物(I)一塩酸塩のF型結晶の調製
実施例2で得られる塩酸塩結晶101mgおよびエタノール5mLをねじ口試験管に添加した。スターラーを用いて60℃にて一日攪拌した。フィルター(0.2μm)を用いて試料をろ取した。得られた固体およびエタノール5mLを再度ねじ口試験管に添加し、スターラーを用いて60℃にて4時間攪拌した。フィルター(0.2μm)を用いてろ取し、標記結晶を得た(75.0mg)。
粉末X線回折ピーク(透過法、2θ±0.2°):5.9°、7.3°、9.3°、10.7°、13.8°、15.6°、16.4°、18.7°、25.1°、26.8°
上記方法により得られた化合物(I)一塩酸塩のF型結晶の粉末X線回折パターンを図7に、熱分析TG-DTAチャートを図17に示す。
化合物(I)一臭化水素酸塩の結晶の調製
化合物(I)933mgをねじ口試験管に添加した。20mLのメタノールに1.5当量(434μL)の臭化水素酸を溶解し、これを試料に添加した。スターラーを用いて、室温にて3日間攪拌した。フィルター(0.2μm)を用いて試料をろ取し、60℃で1時間乾燥させて標記結晶を得た(1111mg)。
粉末X線回折ピーク(透過法、2θ±0.2°):6.0°、7.8°、10.0°、11.7°、17.8°、20.8°、23.5°、24.5°、25.2°、27.3°
上記方法により得られた化合物(I)一臭化水素酸塩の粉末X線回折パターンを図8に、熱分析TG-DTAチャートを図18に示す。
ラット胎仔脳由来神経細胞培養系におけるNGF存在下Acetylcholine(ACh)放出量の測定
(1)ラット初代神経細胞培養
胎生18日齢のSprague-Dawley系(SD)ラット(日本チャールズリバー社)より中隔野を単離し培養に供した。具体的には、イソフルラン麻酔下、妊娠ラットより無菌的に胎仔を摘出した。胎仔より脳を摘出し、氷冷L-15 medium(11415-064、Thermo Fisher Scientific)に浸した。その摘出脳から、実体顕微鏡下で中隔野を採取した。採取した中隔野を、0.25% trypsin(15050-065、Thermo Fisher Scientific)および0.01% DNase(D5025-150KU,Sigma)を含有した酵素溶液中、37℃下30分間の酵素処理することにより、細胞を分散させた。この際、酵素反応は非働化済みウマ血清(26050-088、Thermo Fisher Scientific)を加えることで停止させた。この酵素処理溶液を1000rpmにて3分間遠心分離し、上清を除いた。得られた細胞塊に培地を10mL加えた。培地にはDulbecco‘s Modified Eagle’s Medium(044-29765、WAKO)にN2サプリメント(17502-048、Thermo Fisher Scientific)と1mM Sodium pyruvate(11360-070、Thermo Fisher Scientific)およびPenicilin streptmycin(15140-1221、Thermo Fisher Scientific)を用いた。培地が加えられた細胞塊を、緩やかなピペッティング操作により細胞を再分散後、再度1000rpmにて3分間遠心分離し、上清を除いた。得られた細胞塊に培地を10mL加え、この細胞分散液を40μmナイロンメッシュ(Cell Strainer)でろ過し、細胞塊を除くことにより神経細胞懸濁液を得た。この神経細胞懸濁液を培地にて希釈し、10%非働化済みウシ血清(26140-079、Thermo Fisher Scientific)と10%非働化済みウマ血清を加えた。その後、予めpoly-D-lysineにてコーティングされた96well培養器(354461、CORNING)に初期培養密度が1.4×105cells/cm2になるように100μL/wellにて播種した。播種した細胞は5%CO2-95%air下、37℃インキュベータ中にて二日培養した後、培地全量を新鮮な培地120μLと交換し、引き続き5日間培養した。
(2)化合物添加
培養7日目に薬物添加を以下の通りに行った。試験化合物のDMSO溶液を培地にて最終濃度の10倍になるように希釈した。NGF(450-01、PEPRO TECH,INC.)を0.3ng/mLに調製した。これらの2つの溶液をそれぞれ15μL/well添加し、よく混和した。最終DMSO濃度は0.1%以下とした。また、対照群にはDMSOおよびNGFのみを添加した。
(3)ACh放出量測定
薬物添加1日後に、以下の方法でHPLCにてACh放出量を測定した。培地回収後のwellに温めたバッファーを100μL/well加え、直ぐにバッファーを除いた。その後、10μM choline、10μM physostigmineと6mM KClを加えたバッファーを120μL/well加えた。バッファーは、125mM NaCl、25mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid、1.2mM KH2PO4、1.2mM MgSO4、2.2mM CaCl2(2H2O)、10mM Glucoseに滅菌水にて調製し、溶液の最終pHを7.4にした。バッファーを加えた96well培養器を5%CO2-95%air下、37℃インキュベータ中にて40分間インキュベートした後、80μLを回収した。回収したバッファーに内部標準液IPHC(5×10-7M)を6μL加え、HPLC測定用チューブにバッファーを移し、HPLC測定に供した。結果は、対照群のバッファー中ACh濃度に対する百分率(% of control)にて化合物の作用を示し、対照群のバッファー中ACh濃度に対して20%の上昇を示した参考例1の化合物濃度は0.1μMであった。
(1)化合物投与
本試験では体重約250-350gのSD雄性ラット(日本チャールズリバー社)を使用した。試験化合物は0.01N塩酸に溶解し、経口投与した。
(2)サンプリング
試験化合物投与24時間目に、ペントバルビタール麻酔下で脳組織を摘出した。氷冷下で中隔野を分画し、液体窒素で凍結後-80℃にて保管した。
(3)ChAT mRNA発現量の測定
RNA精製にはRNeasy(登録商標) Plus Mini Kit(#74136:QIAGEN社)を使用した。RNA精製はキットの添付文書に記載の方法にて実施した。RNA精製後、total RNA濃度はQIAxpert Instrument(QIAGEN社)で測定した。cDNAはSuperScript(登録商標) VILOTM cDNA Synthesis Kit(#11754:Thermo Fisher Scientific)を使用して調製した。cDNAの調製はキットの添付文書に記載の方法で実施した。調製したcDNAをRNase free waterで4倍希釈し、希釈したcDNA溶液をサンプルとした。Taqman(登録商標) Universal PCR Master Mix(#4304437:Thermo Fisher Scientific)、Taqman(登録商標) Gene Expression Assays,INVENTORIED(#4331182:Thermo Fisher Scientific)、RNase free waterおよびcDNA溶液をそれぞれ10μL、1μL、4μLおよび5μlずつ混和し、測定サンプル溶液とした。Quantitative polymerase chain reaction(qPCR)はABI PRISM(登録商標) 7900HT(Thermo Fisher Scientific)を使用し、蛍光プローブ法で実施した。解析はSDS2.4(Thermo Fisher Scientific)で実施した。結果は媒体投与群のChAT mRNA発現量に対しての参考例1の化合物投与群のChAT mRNA発現量の増加量を百分率で算出すると10mg/kgで56.4%であった。
(1)背景
脳内とCerebrospinal fluid(CSF)中の神経伝達物質の増減は相関することが齧歯類の研究から明らかとなり、その相関はヒトにおいても同様に捉えられることが明らかとなっている(Lowe S et al. Psychopharmacology 219 (2012) 959-70.)。そこで、試験化合物による脳内のアセチルコリン量変化を検出するために、CSF中アセチルコリン量変化を評価した。
(2)化合物投与
本試験では体重約150-250gのFischer344系雄性ラット(日本チャールズリバー社)を使用した。試験化合物は1日1回、3日間、10mg/kg経口投与した。媒体は0.01N塩酸を使用した。
(3)サンプリング
媒体および試験化合物の最終投与24時間後に、ペントバルビタール麻酔下で大槽からAChE阻害剤入りのチューブにCSFを採取した。採取したCSFを3500xg、4℃で10分間遠心し、上清を回収した。回収した上清を液体窒素で凍結後、-80℃にて保管した。
(4)LCMSを用いたACh測定
内標準物質としてCSF 10μLに最終濃度0.34nmol/L acetylcholine-d9 chloride(ACh-d9)を50μL加えた。ピペッティングにて混和後、1200xg、4℃で10分間遠心した。上清を回収し,LC/MS法(NexeraX2(MS)、TSQ Altis(HPLC))により、AChはprecursor ion m/z 146.050、product ion m/z 87.071を(内標のACh-d9はprecursor ion m/z 155.088、product ion m/z 87.000)を検出した。結果は、媒体投与群のCSF中ACh濃度に対しての参考例1の化合物投与群のCSF中ACh濃度増加を百分率(% of control)で算出すると156.8%であった。
(1)化合物投与
本試験では4ヶ月齢から7ヶ月齢までの約3ヶ月間、Human tau P301S transgenicマウスに1日1回,試験化合物を経口投与した。媒体は0.01N塩酸を使用した。
(2)サンプリング
投与開始日に投与開始時群(4ヶ月齢)、最終投与翌日に媒体投与群および試験化合物投与群にペントバルビタール(50mg/kg,ip)で麻酔後,PBSで経心的に灌流した。灌流後,内側中隔野を含む前脳を採取し,4%パラホルムアルデヒドで固定した。
(3)脳冠状凍結切片作製
採取した内側中隔野を含む前脳を4%パラホルムアルデヒドで一晩浸漬、振とうした後、7.5%スクロース溶液に置換した。翌日に7.5%スクロース溶液に置換し一晩浸漬、振とう後、15%スクロース溶液に置換しさらに一晩浸漬、振とうした。浸漬液を30%スクロース溶液に置換し一晩浸漬、振とう後、内側中隔野を含む前脳のサンプルから滑走式ミクロトーム(Leica,SM2000R)を用いて30μmの厚さの脳冠状凍結切片を作製した。
(4)Choline acetyltransferase(ChAT)陽性細胞数の免疫組織学的定量
作製した脳冠状凍結切片を用いて,一次抗体としてChAT抗体(SantaCruz,SC-20672)を使用し,DAB染色(DAB PEROXIDASE SUBSTRATE KIT(Vector,SK-4100))を行った。オールインワン蛍光顕微鏡(キーエンス,BZ-X710)でThe mouse Brain in stereotaxic coordinates(COMPACT THIRD EDITION, Keith B.J. Franklin & Geroge Paxinos)に示される内側中隔野を含む切片画像を撮影し、BZ解析ソフト(キーエンス)によりその内側中隔野の主軸沿いに存在するChAT陽性細胞数の計測を行った。結果は投与開始時群(4ヶ月齢)のChAT陽性細胞数を100%としたときの媒体投与群と試験化合物投与群のChAT陽性細胞数を百分率で示した。結果は平均値±標準誤差で表した。投与開始時群と媒体投与群間の差(有意差あり:*)および媒体投与群と試験化合物群の差(有意差あり:#)はそれぞれ対応のないt検定で解析した。p<0.05を統計学的有意差として判断した。統計解析はGraphPad Prism version 7.02を用いて行った。結果を表1に示す。
(1)ラット海馬采-脳弓切断モデルの作製
本試験では体重約250-350gのSprague-Dawley系雄性ラット(日本チャールズリバー社)を使用した。ラットをミダゾラム2mg/kg皮下投与、塩酸メデトミジン0.15mg/kg皮下投与、酒石酸ブトルファノール2.5mg/kg皮下投与の三種を混合して麻酔し、脳定位固定装置(株式会社ナリシゲ)に固定した。頭蓋を露出し、Bregmaより2mm後方の正中線から右側頭蓋骨を横幅5mmにドリルで穴をあけた。4mm幅のカミソリをBregmaより深さ5.5mmに刺入し、海馬采-脳弓を切断した。止血後、頭皮を縫合し、手術後ラットをケージにもどし麻酔から回復させた。Bregmaより2mm後方の正中線から右側頭蓋骨を横幅5mmにドリルで穴をあけ、カミソリを刺入しない群を偽手術群とした。
(2)化合物投与
手術5日後から9日間(実施例1:10mg/kg)、または7日後から14日間(実施例3:3mg/kg)、1日1回、試験化合物を経口投与した。媒体は0.01N塩酸を使用し、偽手術群も化合物同様に1日1回、媒体を経口投与した。
(3)サンプリング
ペントバルビタール麻酔下で氷冷PBSで経心的に灌流した。灌流後,内側中隔野を含む前脳を採取し,4%パラホルムアルデヒドに一晩浸漬、振とうした。翌日に7.5%スクロース溶液に置換し一晩浸漬、振とう後、15%スクロース溶液に置換しさらに一晩浸漬、振とうした。浸漬液を30%スクロース溶液に置換し一晩浸漬、振とう後、内側中隔野を含む前脳のサンプルから滑走式ミクロトーム(Leica,SM2000R)を用いて30μmの厚さの脳冠状凍結切片を作製した。
(4)Choline acetyltransferase(ChAT)陽性細胞数およびvesicular acetylcholine transporter〈VAChT〉の免疫組織学的定量
作製した脳冠状凍結切片を用いて,一次抗体としてChAT抗体(SantaCruz,SC-20672)またはVAChT抗体(Merck Millipore,ABN100)を使用し,DAB染色(DAB PEROXIDASE SUBSTRATE KIT(Vector,SK-4100))を行った。オールインワン蛍光顕微鏡(キーエンス,BZ-X710)でThe Rat Brain in stereotaxic coordinates (COMPACT THIRD EDITION, GEORGE PAXINOS & CHARLES WATSON)に示される内側中隔野または海馬を含む切片画像を撮影し、BZ解析ソフト(キーエンス)により内側中隔野のChAT陽性細胞数または海馬VAChTの光学密度(Optical density,OD)の計測を行った。結果は、偽手術群の内側中隔野ChAT陽性細胞数または海馬VAChTのODを100%としたときの媒体投与群と試験化合物投与群のChAT陽性細胞数または海馬VAChTのODを百分率で示した。結果は平均値±標準誤差で表した。媒体投与群と試験化合物群の差(有意差あり:#)はそれぞれ対応のないt検定で解析した。p<0.05を統計学的有意差として判断した。統計解析はGraphPad Prism version 7.02を用いて行った。結果を表2、表3に示す。
Claims (15)
- 請求項1記載の塩または請求項2~14のいずれか一項に記載の結晶を含有する医薬組成物。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2020233452A AU2020233452A1 (en) | 2019-03-05 | 2020-03-03 | Salt of pentacyclic compound and crystals thereof |
CA3129764A CA3129764A1 (en) | 2019-03-05 | 2020-03-03 | Salt of pentacyclic compound and crystals thereof |
JP2021504108A JPWO2020179781A1 (ja) | 2019-03-05 | 2020-03-03 | |
KR1020217025603A KR20210135223A (ko) | 2019-03-05 | 2020-03-03 | 펜타시클릭 화합물의 염 및 이의 결정 |
MX2021009774A MX2021009774A (es) | 2019-03-05 | 2020-03-03 | Sal de un compuesto pentaciclico y su cristal. |
CN202080014060.2A CN113646046B (zh) | 2019-03-05 | 2020-03-03 | 五环化合物的盐及其晶体 |
BR112021015979-7A BR112021015979A2 (pt) | 2019-03-05 | 2020-03-03 | Sal de composto pentacíclico e cristal do mesmo |
EP20766851.8A EP3936189A4 (en) | 2019-03-05 | 2020-03-03 | SALT OF A PENTACYCLIC COMPOUND AND CRYSTALS THEREOF |
US17/021,544 US11420980B2 (en) | 2019-03-05 | 2020-09-15 | Salt of pentacyclic compound and crystal thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-039349 | 2019-03-05 | ||
JP2019039349 | 2019-03-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/021,544 Continuation US11420980B2 (en) | 2019-03-05 | 2020-09-15 | Salt of pentacyclic compound and crystal thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020179781A1 true WO2020179781A1 (ja) | 2020-09-10 |
Family
ID=72337486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/008889 WO2020179781A1 (ja) | 2019-03-05 | 2020-03-03 | 五環式化合物の塩およびそれらの結晶 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11420980B2 (ja) |
EP (1) | EP3936189A4 (ja) |
JP (1) | JPWO2020179781A1 (ja) |
KR (1) | KR20210135223A (ja) |
CN (1) | CN113646046B (ja) |
AU (1) | AU2020233452A1 (ja) |
BR (1) | BR112021015979A2 (ja) |
CA (1) | CA3129764A1 (ja) |
MX (1) | MX2021009774A (ja) |
TW (1) | TW202100531A (ja) |
WO (1) | WO2020179781A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112021015975A2 (pt) | 2019-03-05 | 2021-10-05 | Eisai R&D Management Co., Ltd. | Composto heterocíclico pentacíclico |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5424896A (en) * | 1977-07-26 | 1979-02-24 | Bayer Ag | Benzodiazepineediones*preparation and use thereof |
JPH09118621A (ja) * | 1995-06-20 | 1997-05-06 | Jie Iru Pharmaceut Co Ltd | 活性成分としてデヒドロエボジアミン−HClを含有する記憶増強および抗痴呆剤 |
WO2004033666A2 (en) * | 2002-10-11 | 2004-04-22 | Board Of Regents, The University Of Texas System | Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases |
WO2019049869A1 (ja) * | 2017-09-07 | 2019-03-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 五環式化合物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD258234A1 (de) | 1987-03-05 | 1988-07-13 | Univ Leipzig | Verfahren zur herstellung von pyrido/3',2':4,5/thieno/2,3-e/imidazo-/1,2-c/pyrimidinen sowie strukturanaloger -pyrimido/1,2-c/pyrimidine bzw. -1,3-diazepino/1,2-c/pyrimidine |
RU2117670C1 (ru) | 1988-10-31 | 1998-08-20 | Эйсай Ко., Лтд. | Производные триазоло[1,4]диазепина и способы их получения |
TW197442B (ja) | 1990-02-08 | 1993-01-01 | Pfizer | |
US5621100A (en) | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | K-252a derivatives for treatment of neurological disorders |
US5756494A (en) | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
CL2004000348A1 (es) | 1997-04-15 | 2005-01-14 | Cephalon Inc & Kyowa Hakko Kog | Compuesto derivado de estaurosporina bis-n-sustituida, util para potenciar la funcion de neuronas colinergicas, estriadas, del prosencefalo basal y sensoriales. |
CL2004000352A1 (es) | 1998-05-26 | 2005-05-27 | Cephalon Inc & Kyowa Hakko Kog | Uso de compuestos derivados de estaurosporina para potenciar la funcion de neuronas colinergicas, estriadas, de prosencefalo basal y sensoriales. |
FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
WO2006045429A1 (en) | 2004-10-20 | 2006-05-04 | F. Hoffmann-La Roche Ag | Halogen substituted benzodiazepine derivatives |
BR112021015975A2 (pt) | 2019-03-05 | 2021-10-05 | Eisai R&D Management Co., Ltd. | Composto heterocíclico pentacíclico |
-
2020
- 2020-03-03 EP EP20766851.8A patent/EP3936189A4/en active Pending
- 2020-03-03 CA CA3129764A patent/CA3129764A1/en active Pending
- 2020-03-03 JP JP2021504108A patent/JPWO2020179781A1/ja active Pending
- 2020-03-03 WO PCT/JP2020/008889 patent/WO2020179781A1/ja active Application Filing
- 2020-03-03 CN CN202080014060.2A patent/CN113646046B/zh active Active
- 2020-03-03 BR BR112021015979-7A patent/BR112021015979A2/pt unknown
- 2020-03-03 KR KR1020217025603A patent/KR20210135223A/ko active Search and Examination
- 2020-03-03 AU AU2020233452A patent/AU2020233452A1/en active Pending
- 2020-03-03 TW TW109106928A patent/TW202100531A/zh unknown
- 2020-03-03 MX MX2021009774A patent/MX2021009774A/es unknown
- 2020-09-15 US US17/021,544 patent/US11420980B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5424896A (en) * | 1977-07-26 | 1979-02-24 | Bayer Ag | Benzodiazepineediones*preparation and use thereof |
JPH09118621A (ja) * | 1995-06-20 | 1997-05-06 | Jie Iru Pharmaceut Co Ltd | 活性成分としてデヒドロエボジアミン−HClを含有する記憶増強および抗痴呆剤 |
WO2004033666A2 (en) * | 2002-10-11 | 2004-04-22 | Board Of Regents, The University Of Texas System | Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases |
WO2019049869A1 (ja) * | 2017-09-07 | 2019-03-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 五環式化合物 |
Non-Patent Citations (34)
Also Published As
Publication number | Publication date |
---|---|
US11420980B2 (en) | 2022-08-23 |
AU2020233452A1 (en) | 2021-09-02 |
CN113646046A (zh) | 2021-11-12 |
JPWO2020179781A1 (ja) | 2020-09-10 |
BR112021015979A2 (pt) | 2021-10-05 |
US20210024541A1 (en) | 2021-01-28 |
TW202100531A (zh) | 2021-01-01 |
KR20210135223A (ko) | 2021-11-12 |
MX2021009774A (es) | 2021-09-08 |
EP3936189A1 (en) | 2022-01-12 |
CA3129764A1 (en) | 2020-09-10 |
CN113646046B (zh) | 2024-05-17 |
EP3936189A4 (en) | 2022-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5599610B2 (ja) | Hsp90の阻害による神経変性疾患の処置 | |
TWI707859B (zh) | 五環化合物 | |
JP4465188B2 (ja) | 新規な化合物 | |
EP2388001A2 (en) | Age retardant containing heterocyclic compound having specific structure | |
KR20180075630A (ko) | [1,2,4]트리아졸로[1,5-a]피리미딘-7-일 화합물 | |
TW201831183A (zh) | 組蛋白去乙醯酶雙環抑制劑 | |
WO2020179781A1 (ja) | 五環式化合物の塩およびそれらの結晶 | |
ES2948767T3 (es) | Moléculas orgánicas pequeñas para uso en el tratamiento de trastornos neuroinflamatorios | |
US20210171497A1 (en) | Eaat2 activators and methods of using thereof | |
TW202024020A (zh) | 治療神經退化性疾病之方法 | |
US7465738B2 (en) | Compounds useful as promoters of SMN2 | |
KR102352624B1 (ko) | LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물 | |
JP2001002572A (ja) | ニューロトロフィン作用増強剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20766851 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3129764 Country of ref document: CA Ref document number: 2021504108 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021015979 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020233452 Country of ref document: AU Date of ref document: 20200303 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112021015979 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210812 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021123937 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2020766851 Country of ref document: EP Effective date: 20211005 |